Inside GE HealthCare’s Photon-Counting CT Technology

GE Vernova's shares fell 3.42% to $994 on October 7, despite securing a U.S. construction permit for its BWRX-300 small nuclear reactor. The permit, issued by TVA for the Clinch River project, is a regulatory milestone, but commercial success remains uncertain. GE Vernova aims to leverage repeat business from the design, but investors await funded projects and equipment orders to validate the opportunity.

GE HealthCare agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash, expanding its radiopharmaceutical supply chain. The deal, expected to close in H1 2027, includes 15 U.S. manufacturing sites and rights to FAPI-74. GE HealthCare anticipates revenue growth and margin expansion from the acquisition.

GE HealthCare will acquire Sofie Biosciences for $945M in cash, expanding its radiopharmaceutical footprint. Sofie's assets include 15 contract manufacturing sites and theranostics capabilities. The deal is expected to close by July 2027 and is projected to boost GE HealthCare's revenue and earnings.

GE HealthCare agreed to acquire Sofie Biosciences for $945M, expected to close by mid-2027. The deal aims to bolster GE's radiopharmaceutical market position, adding US manufacturing and distribution for PET products. Sofie's FAPI-74 rights in the US are included. GE HealthCare projects revenue and earnings growth from the acquisition, with analyst Ryan Zimmerman calling it infrastructure-focused. This follows Curium's $7B acquisition of Lantheus in August.

Nippon Steel has selected Tenova and GE Vernova to supply the world's largest Consteel® Electric Arc Furnace for its Yawata Area, Kyushu Works. The project supports Nippon Steel's decarbonization strategy, with Tenova providing the furnace and GE Vernova supplying the power system. This marks a significant step in the global shift towards EAF steelmaking, driven by environmental pressures and technological advancements.

GE Healthcare will acquire Sofie Biosciences for $945 million in cash, according to reports. The deal, if completed, will expand GE Healthcare's molecular imaging capabilities. Sofie Biosciences is a private company specializing in positron emission tomography (PET) imaging. GE Healthcare's stock has seen a 21.62% decline year-to-date.